share_log

Avalo Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Goldman Jonathan

Avalo Therapeutics | 3: Initial statement of beneficial ownership of securities

Avalo Therapeutics | 3：首次持股声明
SEC announcement ·  04/03 16:10
Moomoo AI 已提取核心信息
Jonathan Goldman, a director and 10% owner of Avalo Therapeutics, Inc. [AVTX], filed an Initial Statement of Beneficial Ownership of Securities with the SEC on March 27, 2024. The Form 3 filing, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, indicates that no securities are beneficially owned by Goldman. The form was signed by Donald R. Reynolds by power of attorney on April 3, 2024. This filing is a standard procedure for directors and significant shareholders, providing transparency about their holdings in the company.
Jonathan Goldman, a director and 10% owner of Avalo Therapeutics, Inc. [AVTX], filed an Initial Statement of Beneficial Ownership of Securities with the SEC on March 27, 2024. The Form 3 filing, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, indicates that no securities are beneficially owned by Goldman. The form was signed by Donald R. Reynolds by power of attorney on April 3, 2024. This filing is a standard procedure for directors and significant shareholders, providing transparency about their holdings in the company.
Avalo Therapeutics, Inc. [AVTX] 的董事兼10％所有者乔纳森·戈德曼于2024年3月27日向美国证券交易委员会提交了初步的证券实益拥有权声明。表格3申报是1934年《证券交易法》第16（a）条的要求，表明高盛没有实益拥有任何证券。该表格由唐纳德·雷诺兹于2024年4月3日通过委托书签署。该申报是董事和大股东的标准程序，为他们在公司的持股提供了透明度。
Avalo Therapeutics, Inc. [AVTX] 的董事兼10％所有者乔纳森·戈德曼于2024年3月27日向美国证券交易委员会提交了初步的证券实益拥有权声明。表格3申报是1934年《证券交易法》第16（a）条的要求，表明高盛没有实益拥有任何证券。该表格由唐纳德·雷诺兹于2024年4月3日通过委托书签署。该申报是董事和大股东的标准程序，为他们在公司的持股提供了透明度。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息